gold has been researched along with Prostatic Neoplasms, Castration-Resistant in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Fan, Y; Gao, Y; Jian, Y; Li, L; Liu, D; Ma, B; Ma, J; Wang, Z; Wei, Y; Xu, S; Zhang, D | 1 |
| Al-Rejaie, SS; Baker, A; Elgorban, AM; Mohany, M; Sajid Khan, M; Syed, A | 1 |
| Cao, W; Cui, D; Hou, N; Li, W; Liu, B; Liu, Y; Tan, H; Wang, Z; Xu, B; Zheng, D | 1 |
3 other study(ies) available for gold and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
De Novo Design of an Androgen Receptor DNA Binding Domain-Targeted peptide PROTAC for Prostate Cancer Therapy.
Topics: Animals; DNA; Gold; Hormones; Humans; Male; Peptides; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Proteolysis; Receptors, Androgen; Recombinant Fusion Proteins | 2022 |
Survivin-targeted nanomedicine for increased potency of abiraterone and enzalutamide against prostate cancer.
Topics: Gold; Humans; Male; Metal Nanoparticles; Nanomedicine; Prostatic Neoplasms, Castration-Resistant; Survivin | 2023 |
CD133 antibody targeted delivery of gold nanostars loading IR820 and docetaxel for multimodal imaging and near-infrared photodynamic/photothermal/chemotherapy against castration resistant prostate cancer.
Topics: AC133 Antigen; Animals; Cell Line, Tumor; Combined Modality Therapy; Disease Models, Animal; Docetaxel; Drug Delivery Systems; Gold; Heterografts; Humans; Indocyanine Green; Male; Mice; Molecular Targeted Therapy; Multimodal Imaging; Nanoparticles; Photochemotherapy; Photothermal Therapy; Prostatic Neoplasms, Castration-Resistant | 2020 |